Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?

Peritoneal Dialysis International

Volumn 19, Issue 2, 1999, Pages 180-182

  Weissgarten, Joshua ^a   Zaidenstein, Ronit ^a   Fishman, Sigal ^a   Dishi, Victor ^a   Michovitz Koren, Maya ^a   Averbukh, Zhan ^a   Golik, Ahuva ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CALCIUM CARBONATE; CHOLESTEROL; COLECALCIFEROL; CREATINE KINASE; FIBRIC ACID DERIVATIVE; MEVINOLIN; NIFEDIPINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATINE KINASE BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0033367687     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900222     Document Type: Article

References (14)

1. Moncrief JW, Popovich RP, Dombros NV. Continuous ambulatory peritoneal dialysis. In: Gokal R, Nolph KD, eds. The textbook of peritoneal dialysis. Dordrecht: Kluwer Academic, 1994.
2. Morrison G. Metabolic effects of continuous ambulatory peritoneal dialysis. Ann Rev Med 1989; 40:163-72.
3. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid lowering therapy in patients with renal disease. Kidney Int 1995; 48:188-98.
4. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34:155-62.
5. Malnick SDH, Badir A, Landau Z. Bezafibrate-induced rhabdomyolysis (Letter). Ann Pharmacother 1991; 25:869-70.
6. Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient (Letter). Nephron 1996; 73:736.
7. Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37:847-53.
8. Gorriz JL, Sancho A, Alcoy E, Garcia-Ramos JL, Pallardo LM. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment (Letter). Nephrol Dial Transplant 1995; 10:2371-2.
9. Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J. Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 1992; 51:536-8.
10. Lipkin GW. Severe reversible renal failure with bezafibrate. Lancet 1993; 341:371.
11. Guba EA, Abel SR, Golpen TA. Practical guidelines for therapy in dialysis. Semin Dial 1986; 2:186-8.
12. Li PK, Mak TW, Lam CW, Lai KN. Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13:S428-30.
13. Dimitriadis A, Antoniou S, Hatzisawas N, Pastore F, Kaldi I, Stangou M. The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13:S434-6.
14. Bailey DG, Spence JD, Munoz C. Interaction of citrus juice with felodipine and nifedipine. Lancet 1991; 337:268-9.